Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 154 articles: HTML format

Single Articles

March 2026
1. WANG H, Rajagopal A, Cao K, Cimolai K, et al
   Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.
   BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15854.
   PubMed    
   
   
   
2. DEMARK-WAHNEFRIED W, Rogers LQ, Zubkoff L, Pisu M, et al
   Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15851.
   PubMed    
   
   
   
3. SODERKVIST K, Zia M, Gunnlaugsson A, Josefsson A, et al
   Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15906.
   PubMed     Abstract available
   
   
   
4. HAKEM ZADEH F, Shah N, Bird V
   Prostate cancer and CAR-T therapy: a systematic review.
   BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15703.
   PubMed    
   
   
   
5. WENZEL M, Filzmayer M, Siech C, Le QC, et al
   Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and >/= 10 bone metastases receiving apalutamide: a real-world cohort.
   BMC Cancer. 2026 Mar 2. doi: 10.1186/s12885-026-15803.
   PubMed     Abstract available
   
   
   February 2026
6. WANG C, Zhang YY, Wang HQ, Huang C, et al
   AHSP as a novel non-invasive urinary biomarker for prostate cancer.
   BMC Cancer. 2026 Feb 27. doi: 10.1186/s12885-026-15796.
   PubMed    
   
   
   
7. WANG X, Xu X, Fang S, Shi X, et al
   Inhibition of nuclear import suppresses androgen receptor action and overcomes resistance in prostate cancer.
   BMC Cancer. 2026 Feb 25. doi: 10.1186/s12885-026-15792.
   PubMed    
   
   
   
8. WANG J, Chen X, Yang G, Wang X, et al
   Identification of glycolysis -correlative features for predicting prognosis and investigating immune landscape in prostate cancer.
   BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-026-15723.
   PubMed    
   
   
   
9. MALYGINA H, Salazar Zuniga B, Auerbach H, Ries M, et al
   Clinical experience with an online adaptive radiotherapy for prostate cancer: successful treatment time optimization.
   BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15768.
   PubMed     Abstract available
   
   
   
10. YU C, Wen Y, Li Y, Song B, et al
    Deciphering the eRNA landscape and revealing target aberrant pathways in prostate cancer.
    BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15675.
    PubMed     Abstract available
    
    
    
11. BIAN L, Liu F, Huang X, Peng Y, et al
    Noninvasive preoperative risk stratification of prostate cancer via a foundational model based deep learning with PSMA PET/CT.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15715.
    PubMed    
    
    
    
12. LI G, Li B, Zhang X, Jia J, et al
    Prognostic value of systemic immune-inflammation index and prognostic nutritional index in advanced prostate cancer: development and validation of a comprehensive nomogram.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15701.
    PubMed    
    
    
    January 2026
13. JIANG S, Su S, Wang D
    C21orf2 as a potential regulator of JAK2/STAT3 signaling in prostate cancer cell proliferation and apoptosis: an exploratory study.
    BMC Cancer. 2026 Jan 29. doi: 10.1186/s12885-026-15637.
    PubMed     Abstract available
    
    
    
14. LIU W, Kong W, Jiang S, Wei Y, et al
    Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer.
    BMC Cancer. 2026;26:97.
    PubMed     Abstract available
    
    
    
15. ZHONG X, Xiong Y, Yang F, Yang Y, et al
    Prostate health index enhances prostate cancer management in Chinese populations: evidence from the nation's large cohort and transnational multicohort harmonization.
    BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-026-15577.
    PubMed    
    
    
    
16. ALTINOZ HB, Sanlier N
    Green tea catechins and prostate cancer: mechanisms, clinical evidence, and safety: a narrative review.
    BMC Cancer. 2026 Jan 8. doi: 10.1186/s12885-025-15516.
    PubMed     Abstract available
    
    
    
17. AYALEW TL, Feleke MG, Ashager K, Eshetu A, et al
    Prostate cancer screening and associated factors in Ethiopia: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 7. doi: 10.1186/s12885-025-15480.
    PubMed     Abstract available
    
    
    
18. MATSUDA K, Ogata T, Kamitani N, Watanabe K, et al
    Retrospective analysis of high-dose-rate brachytherapy for patients with prostate cancer aged >/= 75 years.
    BMC Cancer. 2026 Jan 7. doi: 10.1186/s12885-025-15533.
    PubMed    
    
    
    December 2025
19. AVASTHI KK, Manley BJ, Pellini B, Zhang J, et al
    Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15492.
    PubMed     Abstract available
    
    
    
20. MALEKI M, Mardani A, Sadeghi N, Allahmoradi Z, et al
    The impact of digital interactive interventions on survivorship outcomes in prostate cancer: a systematic narrative review.
    BMC Cancer. 2025 Dec 22. doi: 10.1186/s12885-025-15486.
    PubMed     Abstract available
    
    
    
21. OLIVA M, Boitano M, Carbone A, Briata IM, et al
    Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer. a real-world study with implications for cancer prevention/interception.
    BMC Cancer. 2025 Dec 18. doi: 10.1186/s12885-025-15396.
    PubMed     Abstract available
    
    
    
22. ABDELRAHMAN M, Shafaa MW, Abdelrahman H, Ibrahim M, et al
    Positively charged liposomal beta-carotene enhances irradiation-induced cytotoxicity against prostate carcinoma cells: an in-vitro study.
    BMC Cancer. 2025 Dec 10. doi: 10.1186/s12885-025-15244.
    PubMed    
    
    
    
23. RAEISVANDI A, Omidi S, Javaheri M, Moradi H, et al
    Updated dose-response meta-analysis of sexual activity and prostate cancer risk.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15410.
    PubMed     Abstract available
    
    
    November 2025
24. KOCAK T, Acar-Tek N, Yesil S, Ergun MA, et al
    Could GSTP1, PTEN and NKX3.1 gene expression be novel markers in the relationship between prostate cancer and epigenetics?
    BMC Cancer. 2025;25:1825.
    PubMed     Abstract available
    
    
    
25. DOZIE INS, Chukwuocha UM, Innocent DC, Dozie UW, et al
    A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.
    BMC Cancer. 2025 Nov 26. doi: 10.1186/s12885-025-15358.
    PubMed    
    
    
    
26. ZHANG K, Wu K, Zhao C, Wang F, et al
    ACTC1 promotes tumor progression by upregulating BMP4 expression in prostate cancer.
    BMC Cancer. 2025 Nov 24. doi: 10.1186/s12885-025-15336.
    PubMed    
    
    
    
27. WAWRYK O, Collins IM, Lee A, Buzza M, et al
    Rural variations in primary care prostate cancer diagnosis and survival: a cohort study using linked Australian primary care electronic medical record data.
    BMC Cancer. 2025;25:1809.
    PubMed     Abstract available
    
    
    
28. ZHAI CF, Yang X, Qi X, Yang HK, et al
    Quantification of intratumoral heterogeneity using habitat-based MRI radiomics for predicting high-Gleason scores and castration-resistant PCa: retrospective study.
    BMC Cancer. 2025;25:1927.
    PubMed     Abstract available
    
    
    
29. LAPOINTE-BELLEAU A, Rouleau M, Villeneuve L, Descarreaux J, et al
    Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer.
    BMC Cancer. 2025;25:1786.
    PubMed     Abstract available
    
    
    
30. LEE S, Park I, Ahn B, Lim B, et al
    Evaluation of intraductal carcinoma and invasive cribriform carcinoma as predictors of genetic mutations in systemic treatment-naive prostate cancer patients.
    BMC Cancer. 2025;25:1736.
    PubMed     Abstract available
    
    
    
31. HUA J, Qian Y, Lu Y, Zhang Q, et al
    Cross-tissue transcriptome-wide association studies identify genetic susceptibility genes for prostate cancer.
    BMC Cancer. 2025;25:1708.
    PubMed     Abstract available
    
    
    
32. WANG Y, Wang J, Ren G
    UHRF1 and NF-kappaB signaling in prostate cancer progression insights from bioinformatics and experimental validation.
    BMC Cancer. 2025;25:1697.
    PubMed     Abstract available
    
    
    
33. ROSE-DITE-MODESTINE J, Vallard A, Loger JS, Merle S, et al
    Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort.
    BMC Cancer. 2025;25:1703.
    PubMed     Abstract available
    
    
    October 2025
34. AMIRMOKRI AJ, Loffredo CA, Makambi KH, Dawson NA, et al
    Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1645.
    PubMed     Abstract available
    
    
    
35. CHEN H, Chen J, Lyu F, Ma M, et al
    Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials.
    BMC Cancer. 2025;25:1634.
    PubMed     Abstract available
    
    
    
36. MAROTO JP, Puente J, Conde Moreno A, Juarez A, et al
    Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records.
    BMC Cancer. 2025;25:1618.
    PubMed     Abstract available
    
    
    
37. ESMAELI M, Dehghanpour Dehabadi M
    Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies.
    BMC Cancer. 2025;25:1609.
    PubMed     Abstract available
    
    
    
38. YEBOAH KO, Atawuchugi P, Baah FK, Petershie BE, et al
    The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.
    BMC Cancer. 2025;25:1552.
    PubMed     Abstract available
    
    
    
39. GHOLIZADE M, Yazdani E, Hosseini-Baharanchi FS, Nikoofar A, et al
    Variations in radiomic features of the femoral head and neck during helical tomotherapy in prostate and rectal cancer patients.
    BMC Cancer. 2025;25:1509.
    PubMed     Abstract available
    
    
    
40. SEVEN D, Dalan AB, Bayrak OF
    Targeting GSTM3 for therapeutic potential in advanced prostate cancer.
    BMC Cancer. 2025;25:1493.
    PubMed     Abstract available
    
    
    
41. JIN L, Ma Z, Gao F, Li M, et al
    Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study.
    BMC Cancer. 2025;25:1483.
    PubMed     Abstract available
    
    
    September 2025
42. KIM JK, Park MU, Lee D, Kim HJ, et al
    Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study.
    BMC Cancer. 2025;25:1462.
    PubMed     Abstract available
    
    
    
43. JIN Y, Zhang Y, Wang M, Bai X, et al
    Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto((R))) in advanced prostate cancer: a disproportionality analysis based on the fda's adverse event reporting system (FAERS).
    BMC Cancer. 2025;25:1470.
    PubMed     Abstract available
    
    
    August 2025
44. ICER MA, Kocak T, Acar-Tek N, Yesil S, et al
    Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions.
    BMC Cancer. 2025;25:1395.
    PubMed     Abstract available
    
    
    
45. DENG S, Huang D, Han X, Zhang H, et al
    A novel MRI-based habitat analysis and deep learning for predicting perineural invasion in prostate cancer: a two-center study.
    BMC Cancer. 2025;25:1367.
    PubMed     Abstract available
    
    
    
46. CUI F, Zhang Y, Tang X, Gong D, et al
    Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1286.
    PubMed     Abstract available
    
    
    
47. AHAMED Y, Hossain M, Baral S, Al-Raiyan AU, et al
    The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.
    BMC Cancer. 2025;25:1264.
    PubMed     Abstract available
    
    
    July 2025
48. ZHANG L, Li L, Zhe X, Tang M, et al
    Combination of PI-RADS version 2.1 and amide proton transfer values for the detection of clinically significant prostate cancer.
    BMC Cancer. 2025;25:1249.
    PubMed     Abstract available
    
    
    
49. SYED A, Raza H, Khaskheli HK, Rafique I, et al
    Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1173.
    PubMed     Abstract available
    
    
    
50. RAHBAR K, Schlack K, Bogemann M
    Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study.
    BMC Cancer. 2025;25:1159.
    PubMed    
    
    
    
51. BOEGEMANN M, Bennamoun M, Dourthe LM, Encarnacion JA, et al
    Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer.
    BMC Cancer. 2025;25:1119.
    PubMed     Abstract available
    
    
    
52. LIU D, Lin W, Wei C, Huang Y, et al
    Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1032.
    PubMed     Abstract available
    
    
    
53. SUN C, Sun X, Chen Y, Wu Y, et al
    Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis.
    BMC Cancer. 2025;25:1042.
    PubMed     Abstract available
    
    
    June 2025
54. ZHANG G, Guo X, Zhu C, Li S, et al
    Association between serum 25-hydroxyvitamin D and prostate cancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001-2018.
    BMC Cancer. 2025;25:1014.
    PubMed     Abstract available
    
    
    May 2025
55. SU R, Ye SJ, Wang SY, Zhang ZL, et al
    Ten-year follow-up of atypical small acinar hyperplasia cases diagnosed by initial prostate biopsy.
    BMC Cancer. 2025;25:964.
    PubMed     Abstract available
    
    
    
56. QI P, Zhao J, Zhang H, Liu X, et al
    TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells.
    BMC Cancer. 2025;25:956.
    PubMed     Abstract available
    
    
    
57. LIU Z, Gu WJ, Wan FN, Chen ZZ, et al
    Deep learning network enhances imaging quality of low-b-value diffusion-weighted imaging and improves lesion detection in prostate cancer.
    BMC Cancer. 2025;25:953.
    PubMed     Abstract available
    
    
    
58. CHAI L, Yao X, Yang X, Na R, et al
    Synthesizing [(18)F]PSMA-1007 PET bone images from CT images with GAN for early detection of prostate cancer bone metastases: a pilot validation study.
    BMC Cancer. 2025;25:907.
    PubMed     Abstract available
    
    
    
59. ZHAI J, Liu S, Wang T, Wang Y, et al
    Prognosis, immunological features and potential mechanisms of HKR1 in prostate cancer via single-cell and bulk RNA-sequencing.
    BMC Cancer. 2025;25:822.
    PubMed     Abstract available
    
    
    April 2025
60. QIU Y, Wang Y, Liu J, Sun K, et al
    Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response.
    BMC Cancer. 2025;25:813.
    PubMed     Abstract available
    
    
    
61. WANG J, An H, Tao N
    Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.
    BMC Cancer. 2025;25:795.
    PubMed     Abstract available
    
    
    
62. HUANG Y, Wei C, Chen F, Zhang Y, et al
    Comparing the biopsy strategies of prostate cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:786.
    PubMed     Abstract available
    
    
    
63. FAN Z, Li D, Yan S, Zhao X, et al
    NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial.
    BMC Cancer. 2025;25:768.
    PubMed     Abstract available
    
    
    
64. WANG N, Xu X, Zhong Y, Wan Y, et al
    MBs(NRP2)-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer.
    BMC Cancer. 2025;25:769.
    PubMed     Abstract available
    
    
    
65. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    PubMed     Abstract available
    
    
    
66. WANG Y, Chang Y, Song L, Ren J, et al
    Robotic prostatectomy for large-volume prostates in prostate cancer: a retrospective analysis of 50 cases (>100 ml).
    BMC Cancer. 2025;25:701.
    PubMed     Abstract available
    
    
    
67. XU X, Fei W, Wu M, He Y, et al
    Construction and validation of a nomogram for identifying the patients at risk for rapid progression of advanced hormone-sensitive prostate cancer.
    BMC Cancer. 2025;25:634.
    PubMed     Abstract available
    
    
    
68. BONNEAU M, Steinmeyer Z, Morisseau M, Lozano S, et al
    Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients.
    BMC Cancer. 2025;25:642.
    PubMed     Abstract available
    
    
    
69. LU F, Zhao Y, Wang Z, Feng N, et al
    Biparametric MRI-based radiomics for prediction of clinically significant prostate cancer of PI-RADS category 3 lesions.
    BMC Cancer. 2025;25:615.
    PubMed     Abstract available
    
    
    
70. PANG Y, Li J, Hu H, Ung COL, et al
    Genetic associations of prostate cancer in China: a systematic review.
    BMC Cancer. 2025;25:604.
    PubMed     Abstract available
    
    
    March 2025
71. THOMSEN MT, Busk M, Zhang D, Chiu CL, et al
    The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors.
    BMC Cancer. 2025;25:535.
    PubMed     Abstract available
    
    
    
72. WATANABE K, Kamitani N, Ikeda N, Kawata Y, et al
    Long-term outcomes of salvage high-dose-rate brachytherapy for localized recurrence of prostate cancer following definitive radiation therapy: a retrospective analysis.
    BMC Cancer. 2025;25:524.
    PubMed     Abstract available
    
    
    
73. SEKINE Y, Oka D, Ohtsu A, Nakayama H, et al
    The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo.
    BMC Cancer. 2025;25:521.
    PubMed     Abstract available
    
    
    
74. HUANG Z, Li G, Zhang Z, Gu R, et al
    Retraction Note: beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells.
    BMC Cancer. 2025;25:475.
    PubMed    
    
    
    
75. HUANG H, Wang T, Li W, Wu Z, et al
    Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.
    BMC Cancer. 2025;25:432.
    PubMed     Abstract available
    
    
    February 2025
76. SHENG T, Su H, Yao L, Qu Z, et al
    RhoB regulates prostate cancer cell proliferation and docetaxel sensitivity via the PI3K-AKT signaling pathway.
    BMC Cancer. 2025;25:354.
    PubMed     Abstract available
    
    
    
77. WANG L, Chen SY, Wan S, Li KP, et al
    Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis.
    BMC Cancer. 2025;25:332.
    PubMed     Abstract available
    
    
    
78. WEN Y, Zhan S, Wang S, Yang L, et al
    LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer.
    BMC Cancer. 2025;25:314.
    PubMed     Abstract available
    
    
    
79. WEGENER E, Ng M, Guerrieri M, Showalter TN, et al
    A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.
    BMC Cancer. 2025;25:250.
    PubMed     Abstract available
    
    
    
80. CAO L, He R, Zhang A, Li L, et al
    Development of a deep learning system for predicting biochemical recurrence in prostate cancer.
    BMC Cancer. 2025;25:232.
    PubMed     Abstract available
    
    
    
81. FAN J, Xu K, Jiang Z, Gan C, et al
    Role of (18)F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study.
    BMC Cancer. 2025;25:192.
    PubMed     Abstract available
    
    
    January 2025
82. SCHUMACHER O, Newton RU, Tang C, Chee R, et al
    Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial.
    BMC Cancer. 2025;25:160.
    PubMed     Abstract available
    
    
    
83. VAN DER STARRE CM, Bangma CH, Bijlsma MJ, van den Bergh ACM, et al
    External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
    BMC Cancer. 2025;25:149.
    PubMed     Abstract available
    
    
    
84. MAMMONE G, Borghesi S, Borsellino N, Calio A, et al
    Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies.
    BMC Cancer. 2025;25:127.
    PubMed     Abstract available
    
    
    
85. CHEN Z, Li Z, Dou R, Jiang S, et al
    Personalized optimization of systematic prostate biopsy core number based on mpMRI radiomics features: a large-sample retrospective analysis.
    BMC Cancer. 2025;25:116.
    PubMed     Abstract available
    
    
    
86. LIN TP, Chen PC, Lin CY, Wang BJ, et al
    Prostate cancer cells elevate glycolysis and G6PD in response to caffeic acid phenethyl ester-induced growth inhibition.
    BMC Cancer. 2025;25:95.
    PubMed     Abstract available
    
    
    
87. BOVELL AAN, Ramaliba T, Goodwin SO, Phillip JC, et al
    Incidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.
    BMC Cancer. 2025;25:72.
    PubMed     Abstract available
    
    
    
88. SHAHSHENAS S, Hosseini SM, Yarmohammadi H, Soltanipur M, et al
    Expression of cytokeratin 19 in prostatic adenocarcinoma: a systematic review.
    BMC Cancer. 2025;25:52.
    PubMed     Abstract available
    
    
    
89. LI D, Jian J, Shi M, Chen Z, et al
    Elevated miR-221-3p inhibits epithelial-mesenchymal transition and biochemical recurrence of prostate cancer via targeting KPNA2: an evidence-based and knowledge-guided strategy.
    BMC Cancer. 2025;25:34.
    PubMed     Abstract available
    
    
    December 2024
90. KIRLI BOLUKBAS M, Figen M, Kocak Uzel E
    Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.
    BMC Cancer. 2024;24:1563.
    PubMed     Abstract available
    
    
    November 2024
91. LI C, Jing Z, Guo Q, Zheng Z, et al
    Causal roles of dietary structure and types on prostate cancer risk: A mendelian randomization study.
    BMC Cancer. 2024;24:1476.
    PubMed     Abstract available
    
    
    
92. WU XH, Ke ZB, Chen ZJ, Liu WQ, et al
    Periprostatic fat magnetic resonance imaging based radiomics nomogram for predicting biochemical recurrence-free survival in patients with non-metastatic prostate cancer after radical prostatectomy.
    BMC Cancer. 2024;24:1459.
    PubMed     Abstract available
    
    
    
93. SATO K, Sakamoto S, Saito S, Shibata H, et al
    Time-dependent personalized prognostic analysis by machine learning in biochemical recurrence after radical prostatectomy: a retrospective cohort study.
    BMC Cancer. 2024;24:1446.
    PubMed     Abstract available
    
    
    
94. MEHNERT E, Moller FS, Hofbauer C, Weidlich A, et al
    Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.
    BMC Cancer. 2024;24:1431.
    PubMed     Abstract available
    
    
    
95. NGOWI BN, Mremi A, Mbwambo OJ, Seventh F, et al
    Trend in incidence and clinicopathological characteristics of prostate cancer in Northern Tanzania: analysis from a population based cancer registry data 2015-2021.
    BMC Cancer. 2024;24:1424.
    PubMed     Abstract available
    
    
    
96. BAKENGA A, Natukunda B, Okuku F, Mubiru KR, et al
    Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study.
    BMC Cancer. 2024;24:1404.
    PubMed     Abstract available
    
    
    October 2024
97. SHAO IH, Chen SY, Chen HY, Sheng TW, et al
    Integrating clinical and image-based parameters for prediction of early post-prostatectomy incontinence recovery: simplified nomogram approach.
    BMC Cancer. 2024;24:1344.
    PubMed     Abstract available
    
    
    
98. SHAO YJ, Liao CS, Hsu YC, Chiu YC, et al
    Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer.
    BMC Cancer. 2024;24:1319.
    PubMed     Abstract available
    
    
    
99. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    PubMed     Abstract available
    
    
    
100. LI X, Li Y, Zhang L, Long H, et al
     Single-cell sequencing analysis revealed that NEAT1 was a potential biomarker and therapeutic target of prostate cancer.
     BMC Cancer. 2024;24:1242.
     PubMed     Abstract available
     
     
     
101. ABIKAR A, Mustafa MMS, Athalye RR, Nadig N, et al
     Comparative transcriptome of normal and cancer-associated fibroblasts.
     BMC Cancer. 2024;24:1231.
     PubMed     Abstract available
     
     
     September 2024
102. ZHU Z, Zhu Y, Shi H, Zhou P, et al
     Efficacy of brachytherapy versus radical prostatectomy for localized prostate cancer-propensity score-matched comparison.
     BMC Cancer. 2024;24:1177.
     PubMed     Abstract available
     
     
     
103. DONG J, Ji R, Cui L, Liu G, et al
     Feasibility, safety and effectiveness of robot-assisted radical prostatectomy with a new robotic surgical system: a prospective, controlled, randomized clinical trial.
     BMC Cancer. 2024;24:1194.
     PubMed     Abstract available
     
     
     
104. SHEN C, Zhu X, Chen Z, Zhang W, et al
     Nomogram predicting early urinary incontinence after radical prostatectomy.
     BMC Cancer. 2024;24:1095.
     PubMed     Abstract available
     
     
     August 2024
105. XIAO Y, Lai C, Hu J, Mulati Y, et al
     Integrative analysis regarding the correlation between collagen-related genes and prostate cancer.
     BMC Cancer. 2024;24:1038.
     PubMed     Abstract available
     
     
     
106. GARG R, Williamson M
     The metastasis-promoting P1597L mutation in PlexinB1 enhances Ras activity.
     BMC Cancer. 2024;24:1004.
     PubMed     Abstract available
     
     
     
107. WANG Q, Ketteler S, Bagheri S, Ebrahimifard A, et al
     Diagnostic efficacy of [(99m)Tc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.
     BMC Cancer. 2024;24:982.
     PubMed     Abstract available
     
     
     
108. MURPHY K, Kehoe B, Denieffe S, McGrath A, et al
     'Just because I have prostate cancer doesn't mean that I can't do things' - men's experiences of the acceptability of an exercise intervention for prostate cancer during treatment.
     BMC Cancer. 2024;24:949.
     PubMed     Abstract available
     
     
     
109. JANORAY G, Bruguiere E, Mazurier J, Dudouet P, et al
     Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace(R) balloon, in patients treated with radiotherapy for prostate cancer.
     BMC Cancer. 2024;24:934.
     PubMed     Abstract available
     
     
     July 2024
110. LEE J, Hong J, Kim JW, Lim S, et al
     Investigating miR-6880-5p in extracellular vesicle from plasma as a prognostic biomarker in endocrine therapy-treated castration-resistant prostate cancer.
     BMC Cancer. 2024;24:909.
     PubMed     Abstract available
     
     
     
111. SUN W, Li H, Shi W, Lv Q, et al
     Associations between genetically predicted concentrations of plasma proteins and the risk of prostate cancer.
     BMC Cancer. 2024;24:905.
     PubMed     Abstract available
     
     
     
112. WANG Z, Liu H, Zhu Q, Chen J, et al
     Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
     BMC Cancer. 2024;24:817.
     PubMed     Abstract available
     
     
     
113. KIM JS, Taaffe DR, Galvao DA, Clay TD, et al
     Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study.
     BMC Cancer. 2024;24:784.
     PubMed     Abstract available
     
     
     June 2024
114. HUANG J, Sun J, Wang K, Zheng L, et al
     Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.
     BMC Cancer. 2024;24:774.
     PubMed     Abstract available
     
     
     
115. CI X, Chen S, Zhu R, Zarif M, et al
     Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.
     BMC Cancer. 2024;24:744.
     PubMed     Abstract available
     
     
     
116. YANG J, Xu Z, Zheng W, Li Y, et al
     Identification of the cytoplasmic DNA-Sensing cGAS-STING pathway-mediated gene signatures and molecular subtypes in prostate cancer.
     BMC Cancer. 2024;24:732.
     PubMed     Abstract available
     
     
     
117. XU X, Wang W, He Y, Yao Y, et al
     Prognostic marker VPS72 could promote the malignant progression of prostate cancer.
     BMC Cancer. 2024;24:713.
     PubMed     Abstract available
     
     
     
118. ZHU Q, Chen J, Liu H, Zhao J, et al
     The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
     BMC Cancer. 2024;24:706.
     PubMed     Abstract available
     
     
     
119. CHENG TS, Noor U, Watts E, Pollak M, et al
     Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
     BMC Cancer. 2024;24:676.
     PubMed     Abstract available
     
     
     May 2024
120. FU L, Zhang C, Wang Z, Tao W, et al
     Clinical application of serum tumor abnormal protein in prostate cancer patients.
     BMC Cancer. 2024;24:665.
     PubMed     Abstract available
     
     
     
121. WANG B, Pan J, Zhang T, Ni X, et al
     Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen
     BMC Cancer. 2024;24:643.
     PubMed     Abstract available
     
     
     
122. CUI F, Tang X, Man C, Fan Y, et al
     Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
     BMC Cancer. 2024;24:628.
     PubMed     Abstract available
     
     
     
123. CHE B, Yuan S, Zhang H, Zhai J, et al
     Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
     BMC Cancer. 2024;24:586.
     PubMed     Abstract available
     
     
     
124. OBINATA D, Takayama K, Lawrence MG, Funakoshi D, et al
     Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
     BMC Cancer. 2024;24:554.
     PubMed     Abstract available
     
     
     April 2024
125. IHEANACHO CO, Enechukwu OH
     Role of antihypertensive medicines in prostate cancer: a systematic review.
     BMC Cancer. 2024;24:542.
     PubMed     Abstract available
     
     
     
126. YANG L, Ruan Y, Xu H
     HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
     BMC Cancer. 2024;24:544.
     PubMed     Abstract available
     
     
     
127. COLETTA AM, Simon LH, Maslana K, Taylor S, et al
     Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
     BMC Cancer. 2024;24:493.
     PubMed     Abstract available
     
     
     
128. LIU HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, et al
     Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate c
     BMC Cancer. 2024;24:482.
     PubMed     Abstract available
     
     
     
129. YOU X, Qiu J, Li Q, Zhang Q, et al
     Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.
     BMC Cancer. 2024;24:472.
     PubMed     Abstract available
     
     
     
130. DUAN L, Liu Z, Wan F, Dai B, et al
     Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.
     BMC Cancer. 2024;24:448.
     PubMed     Abstract available
     
     
     
131. FREDMAN E, Icht O, Moore A, Bragilovski D, et al
     SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
     BMC Cancer. 2024;24:431.
     PubMed     Abstract available
     
     
     
132. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
     Correction: Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
     BMC Cancer. 2024;24:419.
     PubMed    
     
     
     March 2024
133. GUZMAN J, Weigelt K, Neumann A, Tripal P, et al
     NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
     BMC Cancer. 2024;24:346.
     PubMed     Abstract available
     
     
     
134. SHEN Z, Yao C, Bai Y, Wang Y, et al
     Transversal approach via a bladder neck and prostate combined longitudinal incision versus standard approach of robotic-assisted radical prostatectomy for localized prostate cancer: a retrospective analysis.
     BMC Cancer. 2024;24:313.
     PubMed     Abstract available
     
     
     
135. CUI F, Qiu Y, Xu W, Zou C, et al
     Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
     BMC Cancer. 2024;24:305.
     PubMed     Abstract available
     
     
     
136. MIYAZAWA Y, Koike H, Oka D, Kawamura H, et al
     Comparison of sexual function after robot-assisted radical prostatectomy and carbon-ion radiotherapy for Japanese prostate cancer patients using propensity score matching.
     BMC Cancer. 2024;24:300.
     PubMed     Abstract available
     
     
     
137. FU Q, Luo L, Hong R, Zhou H, et al
     Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer.
     BMC Cancer. 2024;24:290.
     PubMed     Abstract available
     
     
     
138. KHALIL MIM, Ashour A, Shaala RS, Allam RM, et al
     Effect of health belief model-based educational intervention on prostate cancer prevention; knowledge, practices, and intentions.
     BMC Cancer. 2024;24:289.
     PubMed     Abstract available
     
     
     February 2024
139. HUANG H, Liu Y, Wen Z, Chen C, et al
     Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:261.
     PubMed     Abstract available
     
     
     
140. CHEN J, Yu F, He G, Hao W, et al
     A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
     BMC Cancer. 2024;24:254.
     PubMed     Abstract available
     
     
     
141. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
     Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
     BMC Cancer. 2024;24:191.
     PubMed     Abstract available
     
     
     January 2024
142. LING SW, van der Veldt AAM, Konijnenberg M, Segbers M, et al
     Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
     BMC Cancer. 2024;24:146.
     PubMed     Abstract available
     
     
     
143. WANG J, Liu J, Yuan C, Yang B, et al
     Palmitic acid-activated GPRs/KLF7/CCL2 pathway is involved in the crosstalk between bone marrow adipocytes and prostate cancer.
     BMC Cancer. 2024;24:75.
     PubMed     Abstract available
     
     
     
144. ENKE JS, Gross M, Grosser B, Sipos E, et al
     SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
     BMC Cancer. 2024;24:65.
     PubMed     Abstract available
     
     
     
145. MULATI Y, Lai C, Luo J, Hu J, et al
     Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
     BMC Cancer. 2024;24:44.
     PubMed     Abstract available
     
     
     
146. ZHAO S, Miao M, Wang Q, Zhao H, et al
     The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
     BMC Cancer. 2024;24:30.
     PubMed     Abstract available
     
     
     
147. ZHOU X, Chai K, Zhu H, Luo C, et al
     The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.
     BMC Cancer. 2024;24:8.
     PubMed     Abstract available
     
     
     December 2023
148. DAI X, Shi X, Luo M, Li P, et al
     Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
     BMC Cancer. 2023;23:1241.
     PubMed     Abstract available
     
     
     
149. GUAN A, Santiago-Rodriguez EJ, Chung BI, Shim JK, et al
     Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
     BMC Cancer. 2023;23:1191.
     PubMed     Abstract available
     
     
     November 2023
150. HASANI M, Alinia SP, Khazdouz M, Sobhani S, et al
     Oxidative balance score and risk of cancer: a systematic review and meta-analysis of observational studies.
     BMC Cancer. 2023;23:1143.
     PubMed     Abstract available
     
     
     
151. CHEN Z, Zhang J, Jin D, Wei X, et al
     A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
     BMC Cancer. 2023;23:1138.
     PubMed     Abstract available
     
     
     October 2023
152. HUANG L, Ma B, Zhang C, Shi J, et al
     Unveiling poly(rC)-binding protein 2 as the target protein for curcusone C against prostate cancer: mechanism validation through click chemistry-activity based proteomics profiling approach.
     BMC Cancer. 2023;23:957.
     PubMed     Abstract available
     
     
     
153. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
     Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
     BMC Cancer. 2023;23:927.
     PubMed     Abstract available
     
     
     September 2023
154. WOLFE S, Diven MA, Marciscano AE, Zhou XK, et al
     A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
     BMC Cancer. 2023;23:923.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum